The GLASS study is a retrospective trial involving 123 patients (including 17 patients with ROS1–NSCLC and 106 patients with ALK rearrangement-NSCLC) that has demonstrated the efficacy of lorlatinib in controlling both intra- and extracranial disease with an ORR of 67% in patients receiving lorlatinib as second-line (pretreated with other TKIs or with chemotherapy) and an ORR of 100% in patients receiving lorlatinib as third-line [38]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.